Influence of high-flow nasal cannulae on clinical outcomes in elderly patients with acute respiratory failure: a prognostic risk factor analysis.

IF 16.4 1区化学 Q1 CHEMISTRY, MULTIDISCIPLINARY

Accounts of Chemical Research Pub Date : 2024-08-15 eCollection Date: 2024-01-01 DOI:10.62347/URHG8462

Huili Chen, Meixue Huang, Songping Huang, Xiuyan Zhang, Biyu Wu

{"title":"Influence of high-flow nasal cannulae on clinical outcomes in elderly patients with acute respiratory failure: a prognostic risk factor analysis.","authors":"Huili Chen, Meixue Huang, Songping Huang, Xiuyan Zhang, Biyu Wu","doi":"10.62347/URHG8462","DOIUrl":null,"url":null,"abstract":"Objective: To explore the clinical effects of high-flow nasal cannulae (HFNC) in elderly patients with acute respiratory failure (ARF) and analyze prognostic factors following oxygen therapy.Methods: We enrolled 200 ARF patients between January 2022 and June 2023, dividing them into an observation group (n=125) treated with HFNC, and a control group (n=75) receiving conventional oxygen therapy. We compared vital signs before and after treatment and categorized patients into good and poor prognosis groups to analyze demographic data and prognostic factors.Results: Post-treatment, both groups showed improved vital signs, with the observation group experiencing significantly greater improvements (P<0.05). However, the observation group had a higher incidence of complications compared to controls (P=0.001). Patients with a history of endotracheal intubation or high APACHE II scores were more prevalent in the poor prognosis group (both P<0.05). Logistic regression identified the APACHE II score as a risk factor for poor prognosis, while HFNC emerged as a protective factor.Conclusions: HFNC is a safe and effective therapy that improves vital signs and alleviates hypoxia in elderly ARF patients. The APACHE II score and type of oxygen therapy are significant prognostic factors, with HFNC offering a protective effect.","PeriodicalId":1,"journal":{"name":"Accounts of Chemical Research","volume":null,"pages":null},"PeriodicalIF":16.4000,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11384364/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Accounts of Chemical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.62347/URHG8462","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To explore the clinical effects of high-flow nasal cannulae (HFNC) in elderly patients with acute respiratory failure (ARF) and analyze prognostic factors following oxygen therapy.

Methods: We enrolled 200 ARF patients between January 2022 and June 2023, dividing them into an observation group (n=125) treated with HFNC, and a control group (n=75) receiving conventional oxygen therapy. We compared vital signs before and after treatment and categorized patients into good and poor prognosis groups to analyze demographic data and prognostic factors.

Results: Post-treatment, both groups showed improved vital signs, with the observation group experiencing significantly greater improvements (P<0.05). However, the observation group had a higher incidence of complications compared to controls (P=0.001). Patients with a history of endotracheal intubation or high APACHE II scores were more prevalent in the poor prognosis group (both P<0.05). Logistic regression identified the APACHE II score as a risk factor for poor prognosis, while HFNC emerged as a protective factor.

Conclusions: HFNC is a safe and effective therapy that improves vital signs and alleviates hypoxia in elderly ARF patients. The APACHE II score and type of oxygen therapy are significant prognostic factors, with HFNC offering a protective effect.

查看原文本刊更多论文

高流量鼻插管对老年急性呼吸衰竭患者临床疗效的影响：预后风险因素分析。

目的探讨高流量鼻插管（HFNC）在老年急性呼吸衰竭（ARF）患者中的临床效果，并分析氧疗后的预后因素：我们在2022年1月至2023年6月期间招募了200名ARF患者，将其分为接受HFNC治疗的观察组（n=125）和接受常规氧疗的对照组（n=75）。我们比较了治疗前后的生命体征，并将患者分为预后良好组和预后不良组，分析人口统计学数据和预后因素：结果：治疗后，两组患者的生命体征均有所改善，其中观察组的改善幅度明显更大（结论：HFNC 是一种安全有效的治疗方法：HFNC 是一种安全有效的疗法，可改善老年 ARF 患者的生命体征并缓解缺氧。APACHE II 评分和氧疗类型是重要的预后因素，而 HFNC 具有保护作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Accounts of Chemical Research 化学-化学综合

CiteScore

31.40

自引率

1.10%

发文量

312

审稿时长

2 months

期刊介绍： Accounts of Chemical Research presents short, concise and critical articles offering easy-to-read overviews of basic research and applications in all areas of chemistry and biochemistry. These short reviews focus on research from the author’s own laboratory and are designed to teach the reader about a research project. In addition, Accounts of Chemical Research publishes commentaries that give an informed opinion on a current research problem. Special Issues online are devoted to a single topic of unusual activity and significance. Accounts of Chemical Research replaces the traditional article abstract with an article "Conspectus." These entries synopsize the research affording the reader a closer look at the content and significance of an article. Through this provision of a more detailed description of the article contents, the Conspectus enhances the article's discoverability by search engines and the exposure for the research.